Regulation of fluid and electrolyte balance in hypertension: Role of hormones and peptides

Hypertension: Principles and Practice

Volumn , Issue , 2005, Pages 121-142

  Hall, John E ^a   Granger, Joey P ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747601593     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (94)

1. Guyton AC. Arterial Pressure and Hypertension. Circulatory Physiology II. Philadelphia: W.B. Saunders, 1980.
2. Hall JE, Mizelle HL, Hildebrandt DA, Brands MW. Abnormal pressure natriuresis-a cause or a consequence of hypertension. Hypertension 1990; 15:547-559.
3. Cowley AW Jr. Long-term control of arterial blood pressure. Physiol Rev 1992; 72:231-300.
4. Hall JE, Guyton AC, Brands MW. Pressure-volume regulation in hypertension. Kidney Int 1996; 49(suppl 55):S35-S41.
5. Hall JE, Brands MW, Shek EW. Central role of the kidney and abnormal fluid volume control in hypertension. J Hum Hypertens 1996; 10:633-639.
6. Hall JE, Guyton AC, Brands MW. Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York: Raven Press Ltd., 1995:1451-1475.
7. Laragh JH, Sealey JE. The renin-angiotensin-aldosterone hormonal system and regulation of sodium, potassium, and blood pressure homeostasis. In: Orloff J, Berliner RW, eds. Handbook of Physiology, Section 8, Renal Physiology. Washington, DC: The American Physiological Society, 1973:831-908.
8. Hall JE, Brands MW, Henegar JR. Angiotensin II and long-- term arterial pressure control: the overriding dominance of the kidney. J Am Soc Nephrol 1999; 10:s258-s265.
9. Hall JE. Control of sodium excretion by angiotensin II:intrarenal mechanisms and blood pressure regulation. Am J Physiol 1986; 250:R960-R972.
10. Hall JE, Guyton AC, Smith MJ Jr, Coleman TG. Blood pressure and renal function during chronic changes in sodium intake: Role of angiotensin. Am J Physiol 1980; 239:F271-F280.
11. Hall JE, Granger JP, Hester RL, Coleman TG, Smith MJ Jr, Cross RB. Mechanisms of escape from sodium retention during angiotensin II hypertension. Am J Physiol 1984; 246:F627-F634.
12. Hall JE, Granger JP, Smith MJ Jr, Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone ‘escape.’ Hypertension 1984; 6(suppl I):I183-I192.
13. Hall, JE, Mizelle HL, Woods LL. The renin-angiotensin system and long-term regulation of arterial pressure. J Hypertens 1986; 4:387-397.
14. Hricik DE. Captopril-induced renal insufficiency and the role of sodium balance. Ann Intern Med 1985; 103:222-223.
15. Textor SC, Tarazi RC, Novick AC, Bravo EM, Fouad FM. Regulation of renal haemodynamics and glomerular filtration in patients with renovascular hypertension during converting enzyme inhibition with captopril. Am J Med 1984; 76:29-37.
16. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77:1993-2000.
17. Lewis EM, Hunsicker LG, Bain RP, Rohde ED. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
18. Matsuaka M, Hymes J, Ichikawa I. Angiotensin in progressive renal diseases: theory and practice. J Am Soc Nephrol 1996; 7:2025-2043.
19. Eng E, Veniants M, Floege J, Finerle J, Alpers CE, Menard J, Clozel J, Johnson RJ. Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. Am J Hypertens 1994; 7:177-185.
20. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998; 3:181-188.
21. Griffin KA, Abu-Amarah I, Picken M, Bidani AK. Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent.Hypertension 2003; 41:201-206.
22. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
23. Kurtz TW. False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system? Hypertension 2003; 4:193-196.
24. Schuster VL. Effects of angiotensin on proximal tubular reabsorption. Fed Proc 1986; 45:1444-1447.
25. Harris PJ, Young JA. Dose-dependent stimulation and inhibition of proximal tubular sodium reabsorption by angiotensin II in the rat kidney. Pflugers Arch 1977; 367:295-297.
26. Liu FY, Cogan MG. Angiotensin II stimulates early proximal bicarbonate absorption in the rat by decreasing cyclic adenosine monophosphate. J Clin Invest 1989; 84:83-91.
27. Garvin J. Angiotensin stimulates glucose and fluid reabsorption by rat proximal straight tubules. J Am Soc Nephrol 1990; 1:272-277.
28. 3- cotransport in the rabbit proximal tubule. Proc Natl Acad Sci USA 1990; 87:7912-7920.
29. Schelling JR, Singh H, Marzec R, Linas S. Angiotensin IIdependent proximal tubular sodium transport is mediated by cAMP modulation of phospholipase C. Am J Physiol 1994; 267:C1239-C1245.
30. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension 2002; 39:316-322.
31. Harrison-Bernard LM, Navar LG, Ho MM, Vinson GP, el-Dahr SS. Immunohistochemical localization of angiotensin II, AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol 1997; 273:F170-F177.
32. Capasso G, Unwin R, Ciani F, DeSanto NG, Detommaso G, Russo F, Giebisch G. Bicarbonate transport along the loop of Henle. II. Effects of acid-base, dietary and neurohumoral determinants. J Clin Invest 1994; 94:830-838.
33. +(NH4+)-2Cl-cotransport via 20-HETE and PKC in medullary thick ascending limb. Am J Physiol 1998; 274:C1047-C1056.
34. Peti-Peterdi J, Warnock DG, Bell PD. Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT(1) receptors. J Am Soc Nephrol 2002; 13:1131-1135.
35. Beutler KT, Masilamani S, Turban S, Nielsen J, Brooks HL, Ageloff S, Fenton RA, Packer RK, Knepper MA. Long-term regulation of ENaC expression in kidney by angiotensin II. Hypertension 2003; 41:1143-1150.
36. Schnermann J, Levine DZ. Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide. Annu Rev Physiol 2003; 65:501-529.
37. Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol Regul Integr Comp Physiol 1998; 274:R263-R279.
38. Coleman TG, Hall JE. A Mathematical model of renal hemodynamics and excretory function. In: Iyengar SS, ed. Structuring Biological Systems-a Computer Modeling Approach. Boca Raton: CRC Press, 1992:89-124.
39. Kovacs G, Peti-Peterdi J, Rosivall L, Bell PD. Angiotensin II directly stimulates macula densa Na-2Cl-K cotransport via apical AT(1) receptors. Am J Physiol Renal Physiol 2002; 282:F301-F306.
40. Bell PD, Peti-Peterdi J. Angiotensin II stimulates macula densa basolateral sodium/hydrogen exchange via type 1 angiotensin II receptors. J Am Soc Nephrol 1999; 10(suppl 11):S225-S229.
41. Boldyreff B, Wehling M. Aldosterone: refreshing a slow hormone by swift action. News Physiol Sci 2004; 19:97-100.
42. Zhou ZH, Bubien JK. Nongenomic regulation of ENaC by aldosterone. Am J Physiol Cell Physiol 2001; 281:C1118-C1130.
43. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40:117-123.
44. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissman P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892-896.
45. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41:625-633.
46. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001; 12:308-314.
47. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004; 43:41-47.
48. Knox FG, Granger JP. Control of sodium excretion: An integrative approach. In: Windhager E, ed. Handbook of Renal Physiology. New York: Oxford University Press, 1992:927-967.
49. Vesely DL. Atrial natriuretic peptides in pathophysiological diseases. Cardiovasc Res 2001; 51(4):647-658.
50. Granger JP, Opgenorth TJ, Salazar J, Romero JC, Burnett JC Jr. Long-term hypotensive and renal effects of chronic infusions of atrial natriuretic peptide in conscious dogs. Hypertension 1986; 8:II112-II116.
51. Melo LG, Steinhelper ME, Pang SC, Tse Y, Ackermann U. ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models. Physiol Genomics 2000; 3(1):45-58.
52. Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension 2004; 43(3):525-530.
53. Hoagland KM, Flash AK, Roman RJ. Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension 2003; 42:669-673.
54. Laffer CL, Laniado-Schwartzman M, Wang MH, Nasjletti A, Elijovich F. Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic acid in human salt-sensitive versus salt-resistant hypertension. Circulation 2003; 107:574-578.
55. Laffer CL, Laniado-Schwartzman M, Wang MH, Nasjletti A, Elijovich F. 20-HETE and furosemideinduced natriuresis in salt-sensitive essential hypertension. Hypertension 2003; 41:703-708.
56. Iglarz M, Schiffrin EL. Role of endothelin-1 in hypertension. Curr Hypertens Rep 2003; 5(2):144-148.
57. Granger JP. Endothelin. Am J Physiol Regul Integr Comp Physiol 2003; 285(2):R298-R301.
58. Schiffrin EL. Role of endothelin-1 in hypertension. Hypertension 1999; 34(4 Pt 2):876-881.
59. Kassab S, Miller MT, Novak J, Reckelhoff JF, Clower B, Granger JP. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension 1998; 30(1):397-402.
60. Alexander BT, Cockrell KL, Herrington JN, Granger JP. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol 2001; 280:R1388-R1392.
61. Pollock DM, Pollock JS. Evidence for endothelin involvement in the response to high salt. Am J Physiol Renal Physiol 2001; 281(1):F144-F150.
62. Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 2000; 105(7):925-933.
63. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure inpatients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998; 338:784-790.
64. Schnackenberg CG, Kirchner K, Patel A, Granger JP. Nitric oxide, the kidney, and hypertension. Clin Exp Pharmacol Physiol 1997; 24:600-606.
65. Ortiz PA, Garvin JL. Role of nitric oxide in the regulation of nephron transport. Am J Physiol Renal Physiol 2002; 282(5):F777-F784.
66. Cowley AW Jr, Mori T, Mattson D, Zou AP. Role of renal NO production in the regulation of medullary blood flow. Am J Physiol Regul Integr Comp Physiol 2003; 284(6):R1355-R1369.
67. Granger JP, Alexander BT. Abnormal pressure natriuresis in hypertension: Role of nitric oxide. Acta Physiol Scand 2000; 168(1):161-168.
68. Nakamura T, Alberola A, Granger JP. Role of renal interstitial pressure as a mediator of sodium retention during blockade of endothelium derived nitric oxide hypertension. Hypertension 1993; 21:956-960.
69. Sanders PW. Sodium intake, endothelial cell signaling, and progression of kidney disease. Hypertension 2004; 43(2):142-146.
70. Schnackenberg C, Tabor B, StrongM, Granger JP. Intrarenal NO blockade enhances renin secretion rate by a macula densa mechanism. Am J Physiol 1997; 272:R879-R886.
71. Schnackenberg C, Wilkins C, Granger JP. Role of nitric oxide in modulating the vasoconstrictor actions of angiotensin II in preglomerular and postglomerular vessels in dogs. Hypertension 1995; 26(2):1024-1029.
72. Granger JP, Alberola A, Salazer F, Nakamura T. Control of renal hemodynamics during intrarenal systemic EDNO synthesis blockade. J Cardiovasc Pharmacol 1992; 20:S160-S162.
73. Granger JP, Novak J, Schnackenberg C, Williams S, Reinhart G. Role of renal nerves in mediating the hypertensive effects of nitric oxide synthesis inhibition. Hypertension 1996; 27(2):613-618.
74. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42(6):1075-1081.
75. Wilcox CS. Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 2002; 4(2):160-166.
76. Manning RD Jr, Meng S, Tian N. Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. Acta Physiol Scand 2003; 179(3):243-250.
77. Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2003; 284(4):R893-R912.
78. Romero JC, Reckelhoff JF. State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34(4 Pt 2):943-949.
79. Sedeek M, Alexander BT, Abram SR, Granger JP. Role of oxidative stress in endothelin-induced hypertension in rats. Hypertension 2003; 42:806-810.
80. Garvin JL, Ortiz PA. The role of reactive oxygen species in the regulation of tubular function. Acta Physiol Scand 2003; 179(3):225-232.
81. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11:327-332.
82. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001; 60:329-339.
83. Jequier E. Leptin signaling, adiposity, and energy balance. Ann NY Acad Sci 2002; 967:379-388.
84. Hall JE, Hildebrandt DA, Kuo JJ. Obesity hypertension:role of leptin and sympathetic nervous system. Am J Hypertens 2001; 14:103s-115s.
85. Correia MLG, Morgan DA, Sivitz WI, Mark AL, Haynes WG. Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension 2001; 27:936-942.
86. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31:409-414.
87. Kuo J, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001; 37:670-676.
88. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin-role of adrenergic activity. Hypertension 2002; 39:496-501.
89. Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, Haynes WG. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow mice. J Hypertens 1999; 17:1949-1953.
90. Hall JE, Jones DW, Kuo JJ, daSilva AA, Tallam LS, Liu J. Impact of the obesity epidemic on hypertension and renal disease. Curr Hypertens Rep 2003; 5:386-392.
91. Hall JE, Henegar JR, Dwyer TM, Liu J, daSilva AA, Kuo JJ, Tallam L. Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther 2004; 11:41-54.
92. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptinmediated defects. J Clin Endocrinol Metab 1999; 10:3686-3695.
93. Haynes WG, Morgan DA, Djalali A, Sivitz WI, Mark AL. Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 1999; 33:542-547.
94. Kuo JJ, Silva AA, Hall JE. Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function. Hypertension 2003; 41:768-774.